IRVINE, CA, April 16 /CNW/ - IsoTis, Inc. (NASDAQ: ISOT), the
orthobiologics company, today announced it has appointed James (Jim) P.
Abraham as Senior Vice President of Sales.
Mr. Abraham successfully served the company in the same capacity from
November 2004 until early 2006. He has a 24 year track record in the
orthopaedic industry, and as an executive played a key role in growing sales
at Sulzer Orthopedics from 1991 to 1994, Encore Medical Corp. from 1994 to
1998, Regeneration Technologies, Inc. from 1998 to 2002, and at IsoTis from
2004 to 2006. Jim Abraham left IsoTis to set up his own consultancy firm that
primarily focused on advising a private equity group on M&A and investments in
the orthobiology industry. Mr. Abraham replaces Alan Donze who left IsoTis on
Pieter Wolters, President and CEO of IsoTis said: "We are very pleased at
having succeeded in attracting Jim Abraham to once again take up the
responsibility as our Senior Vice President of Sales. Based on our close
collaboration in the past and his successful work with our sales team, I am
confident that he will provide the leadership to continue to execute our
strategy successfully and to help us attain our goals. "
About IsoTis, Inc.
IsoTis is a leading orthobiologics company that develops, manufactures
and markets proprietary products for the treatment of musculoskeletal diseases
and disorders. IsoTis' current orthobiologics products are bone graft
substitutes that promote the regeneration of bone and are used to repair
natural, trauma-related and surgically-created defects common in orthopedic
procedures, including spinal fusions. IsoTis' current commercial business is
highlighted by its Accell line of products, which the company believes
represents the next generation in bone graft substitution.
Certain statements in this press release are "forward-looking statements"
within the meaning of Section 21E of the Securities Exchange Act of 1934, as
amended, including those that refer to management's plans and expectations for
future operations, prospects and financial condition. Words such as
"strategy," "expects," "plans," "anticipates," "believes," "will,"
"continues," "estimates," "intends," "projects," "goals," "targets" and other
words of similar meaning are intended to identify such forward-looking
statements. One can also identify them by the fact that they do not relate
strictly to historical or current facts. Such statements are based on the
current expectations of the management of IsoTis only. Undue reliance should
not be placed on these statements because, by their nature, they are subject
to known and unknown risks and can be affected by factors that are beyond the
control of IsoTis. Actual results could differ materially from current
expectations due to a number of factors and uncertainties affecting IsoTis'
business, including, but not limited to, a competitive sales and marketing
environment, the timely commencement and success of IsoTis' clinical trials
and research endeavors, delays in receiving U.S. Food and Drug Administration
or other regulatory approvals (a.o. EMEA, CE), including the risk that the FDA
determines that our Accell Putty and Accell TBM products are not human tissue
or class II medical devices, that the Company is unable to obtain 510(k)
clearance for its Accell products, that the FDA requires the Company to obtain
premarket approval of its Accell products prior to continuing their marketing,
that the FDA requires the Company to produce additional clinical data to
support approval or clearance of its products, that the FDA imposes compliance
measures against the Company for the marketing of its Accell products,
including imposing fines and injunctions or causing the Company to recall its
Accell products, market acceptance of IsoTis' products, effectiveness of
IsoTis' distribution channels, development of competing therapies and/or
technologies, the terms of any future strategic alliances, the need for
additional capital, the inability to obtain, or meet, conditions imposed for
required governmental and regulatory approvals and consents. IsoTis expressly
disclaims any intent or obligation to update these forward-looking statements
except as required by law. For a more detailed description of the risk factors
and uncertainties affecting IsoTis, refer to the Annual Report on Form 20-F
for the fiscal year ended December 31, 2005 of IsoTis SA, the predecessor of
the Company, filed with the SEC, to IsoTis SA's reports filed from time to
time with the Swiss Stock Exchange (SWX), Euronext Amsterdam N.V., SEDAR at
www.sedar.com and the Toronto Stock Exchange (TSX), and to the reports filed
from time to time by the Company with the SEC.
For further information:
For further information: Rob Morocco, CFO, (949) 855-7155,
email@example.com; Hans Herklots, Director IR, (949) 855-7195, or